PRTK - Paratek delivers first procurement of NUZYRA to BARDA

Paratek Pharmaceuticals (PRTK) announced that it delivered the first procurement of NUZYRA valued at ~$38M to the Biomedical Advanced Research and Development Authority ((BARDA)).BARDA is part of the Office of the Assistant Secretary for Preparedness and Response ((ASPR)) at the U.S. Department of Health and Human Services ((HHS)).The company expects to recognize the value of procurement in Q2 2021 financials under net sales of NUZYRA.“Paratek continues to execute and deliver on all aspects of this unique public-private partnership with BARDA to develop NUZYRA for the treatment of pulmonary anthrax,” commented Paratek CEO Evan Loh.In 2019, the company signed a five-year contract with BARDA in a deal valued at $284.5M for up to four procurements of NUZYRA.

For further details see:

Paratek delivers first procurement of NUZYRA to BARDA